News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
657,955 Results
Type
Article (50204)
Company Profile (224)
Press Release (607498)
Multimedia
Podcasts (195)
Webinars (29)
Section
Business (178200)
Career Advice (2618)
Deals (32882)
Drug Delivery (165)
Drug Development (79728)
Employer Resources (173)
FDA (16763)
Job Trends (13799)
News (316211)
Policy (32817)
Tag
2027 BioCapital Elite (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
Academia (2467)
Academic (1)
Accelerated approval (49)
Adcomms (39)
Allergies (169)
Alliances (45040)
ALS (212)
Alzheimer's disease (1869)
Antibody-drug conjugate (ADC) (476)
Approvals (17033)
Artificial intelligence (689)
Autoimmune disease (298)
Automation (44)
Bankruptcy (331)
Best Places to Work (10191)
BIOSECURE Act (23)
Biosimilars (235)
Biotechnology (114)
Bladder cancer (188)
Brain cancer (70)
Breast cancer (728)
Cancer (5722)
Cardiovascular disease (486)
Career advice (2215)
Career pathing (48)
CAR-T (315)
CDC (75)
Celiac Disease (2)
Cell therapy (901)
Cervical cancer (46)
Clinical research (69278)
Collaboration (2002)
Company closure (8)
Compensation (1409)
Complete response letters (101)
COVID-19 (2823)
CRISPR (106)
C-suite (1105)
Cystic fibrosis (153)
Data (7638)
Decentralized trials (3)
Denatured (54)
Depression (181)
Dermatology (82)
Diabetes (584)
Diagnostics (6146)
Digital health (50)
Diversity (12)
Diversity, equity & inclusion (43)
Drug discovery (326)
Drug pricing (241)
Drug shortages (38)
Duchenne muscular dystrophy (296)
Earnings (75878)
Editorial (77)
Employer branding (20)
Employer resources (152)
Events (102235)
Executive appointments (1063)
FDA (20496)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (16)
Frontotemporal dementia (31)
Funding (1599)
Gene editing (234)
Generative AI (62)
Gene therapy (747)
GLP-1 (1210)
Government (4442)
Grass and pollen (8)
Guidances (400)
Healthcare (16213)
HIV (84)
Huntington's disease (62)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (101)
Immunology and inflammation (334)
Immuno-oncology (95)
Indications (186)
Infectious disease (3165)
Inflammatory bowel disease (228)
Inflation Reduction Act (15)
Influenza (134)
Intellectual property (282)
Interviews (483)
IPO (15535)
IRA (59)
Job creations (3882)
Job search strategy (1817)
JPM (73)
Kidney cancer (21)
Labor market (101)
Layoffs (647)
Leadership (50)
Legal (7943)
Liver cancer (102)
Longevity (28)
Lung cancer (749)
Lymphoma (420)
Machine learning (55)
Management (59)
Manufacturing (1036)
MASH (200)
Medical device (12089)
Medtech (12190)
Mergers & acquisitions (18543)
Metabolic disorders (1620)
mRNA (233)
Multiple sclerosis (193)
NASH (24)
Neurodegenerative disease (434)
Neuropsychiatric disorders (122)
Neuroscience (3435)
Neurotech (2)
NextGen: Class of 2026 (5544)
Non-profit (3475)
Now hiring (67)
Obesity (803)
Opinion (350)
Ovarian cancer (204)
Pain (253)
Pancreatic cancer (294)
Parkinson's disease (373)
Partnered (29)
Patents (593)
Patient recruitment (667)
Peanut (62)
People (54756)
Pharmaceutical (85)
Pharmacy benefit managers (36)
Phase 1 (21383)
Phase 2 (30114)
Phase 3 (23406)
Pipeline (8413)
Policy (380)
Postmarket research (2615)
Preclinical (8750)
Press Release (50)
Prostate cancer (301)
Psychedelics (67)
Radiopharmaceuticals (319)
Rare diseases (1154)
Real estate (5467)
Recruiting (70)
Regulatory (26012)
Reports (51)
Research institute (2316)
Resumes & cover letters (430)
Rett syndrome (39)
RNA editing (24)
RSV (89)
Schizophrenia (188)
Series A (279)
Series B (206)
Service/supplier (14)
Sickle cell disease (118)
Special edition (31)
Spinal muscular atrophy (176)
Sponsored (52)
Startups (3406)
State (2)
Stomach cancer (21)
Supply chain (133)
Tariffs (104)
The Weekly (138)
Vaccines (1202)
Venture capital (117)
Weight loss (564)
Women's health (112)
Worklife (24)
Date
Today (181)
Last 7 days (909)
Last 30 days (3480)
Last 365 days (30221)
2026 (11983)
2025 (30191)
2024 (33888)
2023 (37952)
2022 (48575)
2021 (52352)
2020 (49727)
2019 (40555)
2018 (30955)
2017 (31272)
2016 (30063)
2015 (33725)
2014 (27398)
2013 (23039)
2012 (24702)
2011 (25296)
2010 (23250)
Location
Africa (806)
Alabama (79)
Alaska (7)
Arizona (291)
Arkansas (14)
Asia (40820)
Australia (6587)
California (12721)
Canada (3317)
China (1327)
Colorado (535)
Connecticut (580)
Delaware (400)
Europe (92987)
Florida (1924)
Georgia (388)
Hawaii (4)
Idaho (48)
Illinois (977)
India (87)
Indiana (534)
Iowa (23)
Japan (536)
Kansas (117)
Kentucky (47)
Louisiana (35)
Maine (79)
Maryland (1552)
Massachusetts (9267)
Michigan (303)
Minnesota (668)
Mississippi (5)
Missouri (133)
Montana (21)
Nebraska (26)
Nevada (132)
New Hampshire (70)
New Jersey (3429)
New Mexico (28)
New York (3310)
North Carolina (1672)
North Dakota (8)
Northern California (6418)
Ohio (359)
Oklahoma (19)
Oregon (38)
Pennsylvania (2474)
Puerto Rico (27)
Rhode Island (40)
South America (1177)
South Carolina (82)
South Dakota (2)
Southern California (5012)
Tennessee (189)
Texas (1949)
United States (44760)
Utah (320)
Virginia (321)
Washington D.C. (81)
Washington State (1009)
West Virginia (4)
Wisconsin (127)
Wyoming (2)
657,955 Results for "ascendis pharma a s".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pipeline
Ascendis retreats to rare endocrinology wheelhouse as cancer plans falter
Before discontinuing the asset, Ascendis Pharma was studying onvapegleukin alfa in advanced or metastatic solid tumors, demonstrating a three- to four-month overall survival advantage over historical controls.
May 8, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Ascendis Pharma Reports First Quarter 2026 Financial Results
May 7, 2026
·
22 min read
Press Releases
Ascendis Pharma to List Ordinary Shares Directly on Nasdaq
April 8, 2026
·
4 min read
Press Releases
Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq
April 20, 2026
·
4 min read
Mergers & acquisitions
Revolution, Ascendis Named Top Buyout Targets as Industry Awaits The Big One
Prime biotech buyout targets such as Revolution Medicines and Ascendis Pharma have recently found themselves in the middle of acquisition rumors—though no deals have panned out so far.
March 19, 2026
·
2 min read
·
Tristan Manalac
C-suite
Lilly, J&J CEOs top pharma’s highest paid list—again
Three pharma CEOs joined the $30 million compensation club in 2025 but Eli Lilly’s David Ricks exceeded his nearest peer by more than $4 million.
May 13, 2026
·
5 min read
·
Annalee Armstrong
Press Releases
Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference
March 2, 2026
·
4 min read
Press Releases
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts
April 8, 2026
·
2 min read
Press Releases
Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results
February 12, 2026
·
14 min read
FDA
FDA Delays Decision on Ascendis’ Dwarfism Drug by Three Months
If approved, Ascendis’ TransCon CNP would become the second therapy for achondroplasia, challenging BioMarin’s Voxzogo.
December 1, 2025
·
1 min read
·
Tristan Manalac
1 of 65,796
Next
